Tuesday, June 25, 2013

VX-509 at the EULAR 2013 Meeting

No, VX-509 isn’t a motor oil, it’s a JAK3 inhibitor. There hadn’t been much at the EULAR 2012 Meeting and nothing at the ACR 2012 Meeting. Link. http://rheumatologe.blogspot.de/2012/07/vx-509-and-eular-2012.html. But VX-509 was sighted again at the EULAR 2013 Meeting.

I. M. Catlett and colleagues presented [THU0160]: “The effect of VX-509, a selective oral JAK3 inhibitor, on plasma biomarkers of disease activity in patients with rheumatoid arthritis.” Conclusions: “VX-509 treatment modulated biomarkers of RA associated with inflammation (IL-6, CD25, and CCL18) and bone erosion (MMP-3). These changes are consistent with the efficacy of VX-509 in improving RA signs and symptoms.” – and then I had a strange feeling … I accessed: http://www.abstracts2view.com/eular/view.php?nu=EULAR13L_THU0160 … and I found the same abstract in the archives of EULAR 2012!

We should ask Vertex if they still want to bring VX-509 to the market. Maybe they should change the motor oil name into a pharmaceutical name. Or maybe it’s also bye-bye VX-509.

No comments:

Post a Comment